Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases
Open Access
- 1 May 1986
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 29 (5) , 955-957
- https://doi.org/10.1128/aac.29.5.955
Abstract
YTR 830, a new beta-lactamase inhibitor, combined with amoxicillin or carbenicillin, showed a synergistic effect similar to that observed with clavulanic acid, and generally better than that with sulbactam, against strains harboring chromosome-encoded penicillinases and broad-spectrum beta-lactamases or plasmid-determined beta-lactamases. With ampicillin, YTR 830 showed the best synergistic activity of the inhibitors against Proteus morganii, Citrobacter freundii, and Enterobacter cloacae and their mutants with a derepressed chromosome-encoded cephalosporinase.This publication has 6 references indexed in Scilit:
- Sch 34343 activity against streptococci and -lactam-resistant EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 1985
- Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillinAntimicrobial Agents and Chemotherapy, 1984
- [Distribution of constituent beta-lactamases in Pseudomonas aeruginosa].1984
- Kinetic studies on inactivation of Citrobacter freundii cephalosporinase by sulbactamAntimicrobial Agents and Chemotherapy, 1983
- Resistance to cephalosporins among gentamicin-resistant klebsiellaeJournal of Antimicrobial Chemotherapy, 1982
- The β-Lactamases of Gram-Negative Bacteria and their Possible Physiological RolePublished by Elsevier ,1973